levomilnacipran
Sign in to saveAlso known as F-2695, Fetzima®, (1S,2R)-milnacipran, (1R,2S)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
Levomilnacipran, sold under the brand name Fetzima, is an antidepressant, used for the treatment of major depressive disorder in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 451552762
- Drug.image
- Levomilnacipran.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.image2
- Levomilnacipran ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.tradename
- Fetzima
- Drug.MedlinePlus
- a613048
- Drug.DailyMedID
- Levomilnacipran
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- N06
- Drug.ATC_suffix
- AX28
- Drug.legal_BR
- C1
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_status
- Rx-only
via Wikipedia infobox
Research
123 papers- Levomilnacipran: More of the Same?The primary care companion for CNS disorders · 2019
- Levomilnacipran.2006
- Levomilnacipran extended release: first global approval.Drugs · 2013
- Levomilnacipran: a newly approved drug for treatment of major depressive disorder.Expert review of clinical pharmacology · 2014
- Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.CNS drugs · 2014
via PubMed
~4 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- History
- Research
- References
- External links
Levomilnacipran, sold under the brand name Fetzima, is an antidepressant, used for the treatment of major depressive disorder in adults. It is the levorotatory enantiomer of milnacipran, and has similar effects and pharmacology, acting as a serotonin–norepinephrine reuptake inhibitor.
Levomilnacipran was approved for medical use in the United States in July 2013.
Excerpted from Wikipedia’s “levomilnacipran” article, available under the CC BY-SA 4.0 licence.